Startups
2016
ADMIT THERAPEUTICS SLTEST FOR AN EARLY AD (ALZHEIMER'S DISEASE) DETECTION
Address
Carrer de Joan XXIII 10, 08950 Esplugues de Llobregat, Spain
Finance Data
CERCA ownership
L'Hospitalet de Llobregat, Spain
2004
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)
CERCA Center Contact
LT
Laia TravesetResponsable innovació
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)Status & Deeptech areas
Company Status & Company Deeptech AreasCurrent company status
DeepTech Area
Spinoff information
Company Description
ADmit Therapeutics, S.L. is a spin-off from the Bellvitge Biomedical Research Institute (IDIBELL), and focused on the development and commercialization of a novel Alzheimer's disease (AD) early detection technology.
ADmit Therapeutics’ vocation consists in building a strong portfolio of projects. The first one will be based in the early AD diagnostic. But ADmit Therapeutics will also work in complementary fields such as Dementia with Lewy bodies and Parkinson Disease, to make its offer more robust and attractive for future acquisitors
ADmit Therapeutics’ vocation consists in building a strong portfolio of projects. The first one will be based in the early AD diagnostic. But ADmit Therapeutics will also work in complementary fields such as Dementia with Lewy bodies and Parkinson Disease, to make its offer more robust and attractive for future acquisitors
Product description
Our diagnostic test represents the determination of biomarkers non-related with β-amyloid nor tau.
Our findings may become a pool of biomarkers very useful for the detection of patients at early stages of AD.
Our findings may become a pool of biomarkers very useful for the detection of patients at early stages of AD.